N-[2-Hydroxy-6-(4-methoxybenzamido)phenyl]-4-(4-methyl-1,4-diazepan-1-yl)benzamide
- Product Name
- N-[2-Hydroxy-6-(4-methoxybenzamido)phenyl]-4-(4-methyl-1,4-diazepan-1-yl)benzamide
- CAS No.
- 365462-23-3
- Chemical Name
- N-[2-Hydroxy-6-(4-methoxybenzamido)phenyl]-4-(4-methyl-1,4-diazepan-1-yl)benzamide
- Synonyms
- YM-150;YM 150);Tanexaban;Darexaban (YM150;Darexaban, Tanexaban;Darexaban, 10 mM in DMSO;N-[2-Hydroxy-6-(4-methoxybenzamido)phenyl]-4-(4-methyl-1,4-diazepan-1-yl)benzamide;N-(3-Hydroxy-2-(4-(4-methyl-1,4-diazepan-1-yl)benzamido)phenyl)-4-methoxybenzamide;N-[2-hydroxy-6-[(4-methoxybenzoyl)amino]phenyl]-4-(4-methyl-1,4-diazepan-1-yl)benzamide;Benzamide, N-[2-[[4-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)benzoyl]amino]-3-hydroxyphenyl]-4-methoxy-
- CBNumber
- CB92484869
- Molecular Formula
- C27H30N4O4
- Formula Weight
- 474.56
- MOL File
- 365462-23-3.mol
N-[2-Hydroxy-6-(4-methoxybenzamido)phenyl]-4-(4-methyl-1,4-diazepan-1-yl)benzamide Property
- Boiling point:
- 557.2±50.0 °C(Predicted)
- Density
- 1.280±0.06 g/cm3(Predicted)
- storage temp.
- Store at -20°C
- solubility
- DMSO : 250 mg/mL (526.81 mM; Need ultrasonic)
- pka
- 9.11±0.40(Predicted)
- form
- Solid
- color
- Off-white to light yellow
N-Bromosuccinimide Price
- Product number
- FD36340
- Product name
- Darexaban
- Packaging
- 5mg
- Price
- $550
- Updated
- 2021/12/16
- Product number
- FD36340
- Product name
- Darexaban
- Packaging
- 10mg
- Price
- $990
- Updated
- 2021/12/16
N-[2-Hydroxy-6-(4-methoxybenzamido)phenyl]-4-(4-methyl-1,4-diazepan-1-yl)benzamide Chemical Properties,Usage,Production
Uses
Darexaban (YM150) is a potent, selective and orally active factor Xa (FXa) inhibitor with an IC50 of 54.6 nM. Darexaban shows high selectivity against other related serine proteases, such as trypsin, thrombin, and kallikrein. Darexaban has anticoagulant and antithrombotic effects[1][2][3].
in vivo
In mice, Darexaban inhibits FXa activity in plasma with an ED50 value of 24.8 mg/kg. Darexaban prolonges prothrombin time (PT) at 3 mg/kg[2].
In a pulmonary thromboembolism (PE) mouse model, Darexaban dose-dependently reduces the mortality rate, significantly so at 10 mg/kg[2].
In a FeCl3-induced venous thrombosis (VT) mouse model, Darexaban (0.3-10 mg/kg) dose-dependently decreases the thrombus protein content, significantly so at doses of 3 mg/kg or higher[2].
References
[1] Fukushi Hirayama, et al. Discovery of N-[2-hydroxy-6-(4-methoxybenzamido)phenyl]-4- (4-methyl-1,4-diazepan-1-yl)benzamide (darexaban, YM150) as a potent and orally available factor Xa inhibitor. J Med Chem. 2011 Dec 8;54(23):8051-65. DOI:10.1021/jm200868m
[2] Seiji Kaku, et al. Darexaban: anticoagulant effects in mice and human plasma in vitro, antithrombotic effects in thrombosis and bleeding models in mice and effects of anti-inhibitor coagulant complex and recombinant factor VIIa. Thromb Res. 2013 May;131(5):450-6. DOI:10.1016/j.thromres.2013.03.016
[3] Milan Remko, et al. Theoretical Study of Molecular Structure and Physicochemical Properties of Novel Factor Xa Inhibitors and Dual Factor Xa and Factor IIa Inhibitors. Molecules. 2016 Feb 4;21(2):185. DOI:10.3390/molecules21020185
N-[2-Hydroxy-6-(4-methoxybenzamido)phenyl]-4-(4-methyl-1,4-diazepan-1-yl)benzamide Preparation Products And Raw materials
Raw materials
Preparation Products
N-[2-Hydroxy-6-(4-methoxybenzamido)phenyl]-4-(4-methyl-1,4-diazepan-1-yl)benzamide Suppliers
- Tel
- --
- Fax
- --
- sales@carbosynth.com
- Country
- United Kingdom
- ProdList
- 6005
- Advantage
- 58